Mark Hopman's most recent trade in Beta Bionics Inc. was a trade of 16,158 Common Stock done at an average price of $16.6 . Disclosure was reported to the exchange on Aug. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 16.61 per share. | 19 Aug 2025 | 16,158 | 34,132 | - | 16.6 | 268,376 | Common Stock |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 19 Aug 2025 | 16,158 | 50,290 | - | 5.1 | 82,406 | Common Stock |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2025 | 16,158 | 67,084 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 02 Jun 2025 | 551 | 34,211 | - | 18.1 | 10,000 | Common Stock |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 17.03 per share. | 02 Jun 2025 | 238 | 34,762 | - | 17.0 | 4,053 | Common Stock |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 18.70 per share. | 02 Jun 2025 | 79 | 34,132 | - | 18.7 | 1,477 | Common Stock |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 52,000 | 52,000 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 35,000 | 35,000 | - | 0 | Common Stock | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 83,242 | 83,242 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 47,775 | 47,775 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 39,424 | 39,424 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 37,229 | 37,229 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 17,765 | 17,765 | - | - | Employee Stock Option (right to buy) | |
| Beta Bionics Inc. | Mark Hopman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 47,775 | 47,775 | - | - | Employee Stock Option (right to buy) |